Egetis Therapeutics AB Stock
Stocks
EGTX
SE0003815604
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq Stockholm
19:00:00 15/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 7.870 SEK | -1.13% |
|
-1.50% | +47.38% |
| 09-14 | Lannebo Hälsa och Ny Teknik rose 5.9% in August, Bico among the month's winners | FW |
| 08-31 | Eight stocks have so far today posted new 52-week highs on the Stockholm Stock Exchange | FW |
| Market Cap | 3.66B 374M 324M 307M 278M 521M 35.91B 525M 1.41B 18.21B 1.41B 1.38B 58.07B | P/E 2026 * |
-9.05x | P/E 2027 * | -17.3x |
|---|---|---|---|---|---|
| Enterprise Value | 3.11B 318M 275M 260M 236M 442M 30.5B 446M 1.2B 15.46B 1.19B 1.17B 49.31B | EV / Sales 2026 * |
5.64x | EV / Sales 2027 * | 10.1x |
| Free-Float |
37.69% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq Stockholm
| EGTX | Delayed | |
CBOE
| Real-time | ||
|
London S.E.
| 0ABW | Delayed | |
|
OTC Markets
| PDPHF | Delayed | |
|
Börse Stuttgart
| P0F | Delayed | |
|
Deutsche Boerse AG
| P0F | Delayed | |
|
CBOE
| 0ABW | Real-time | |
|
Boerse Muenchen
| P0F | Real-time |
Last Transcript: Egetis Therapeutics AB
| 1 day | -1.13% | ||
| 1 week | -1.50% | ||
| Current month | +0.25% | ||
| 1 month | +9.92% | ||
| 3 months | +46.83% | ||
| 6 months | +50.48% | ||
| Current year | +47.38% |
| 1 week | 7.87 |  | 8.2 |
| 1 month | 6.73 | | 8.2 |
| Current year | 4.23 | | 8.2 |
| 1 year | 3.62 | | 8.2 |
| 3 years | 3.02 | | 9.3 |
| 5 years | 3 | | 9.3 |
| 10 years | 3 | | 50.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 16/06/2017 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 47 | 31/12/2017 |
Tiago Nune
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 01/01/2017 | |
Mats Blom
CHM | Chairman | 61 | 06/05/2024 |
Behshad Sheldon
BRD | Director/Board Member | 63 | 01/01/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/2/26 A | Sell | Executive/Senior Manager | -594 | 0.0001% | ||
| 8/31/26 A | Exercice | Chief Financial Officer | 1,099 | 0.0002% | ||
| 8/31/26 A | Buy | Chief Operating Officer | 1,099 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.13% | -1.50% | +57.09% | +79.48% | 374M | |
| -1.38% | +0.20% | +46.42% | +96.33% | 69.18B | |
| -1.04% | -0.81% | +34.61% | +75.16% | 62B | |
| -4.29% | -3.98% | -16.22% | +350.66% | 26.19B | |
| +2.09% | +2.89% | +29.64% | +15.25% | 25.75B | |
| -2.20% | -2.00% | -1.22% | -14.48% | 24.29B | |
| +1.61% | -0.69% | +20.85% | -19.42% | 19.84B | |
| +1.26% | -14.23% | +170.04% | +298.75% | 15.65B | |
| -5.54% | +0.69% | -8.13% | +830.48% | 13.88B | |
| -0.17% | -4.03% | -9.67% | +456.14% | 14.09B | |
| Average | -1.08% | -1.57% | +32.34% | +216.84% | 27.13B | |
| Weighted average by Cap. | -1.11% | -1.31% | +31.39% | +157.88% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 551M 56.38M 48.83M 46.18M 41.81M 78.46M 5.41B 79.05M 212M 2.74B 212M 207M 8.74B | 328M 33.54M 29.05M 27.47M 24.87M 46.67M 3.22B 47.02M 126M 1.63B 126M 123M 5.2B |
| Net income | 161M 16.5M 14.29M 13.51M 12.23M 22.96M 1.58B 23.13M 62.04M 802M 61.97M 60.6M 2.56B | -134M -13.73M -11.9M -11.25M -10.18M -19.11M -1.32B -19.26M -51.65M -668M -51.59M -50.45M -2.13B |
| Net Debt | -552M -56.45M -48.89M -46.23M -41.86M -78.56M -5.41B -79.15M -212M -2.75B -212M -207M -8.76B | -353M -36.12M -31.29M -29.58M -26.78M -50.27M -3.46B -50.65M -136M -1.76B -136M -133M -5.6B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/09/26 | SEK 7.870 | -1.13% | 689,813 |
| 14/09/26 | SEK 7.960 | +0.89% | 524,614 |
| 11/09/26 | SEK 7.890 | -1.99% | 505,531 |
| 10/09/26 | SEK 8.050 | -0.12% | 1,173,584 |
| 09/09/26 | SEK 8.060 | +0.88% | 811,835 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- EGTX Stock
Select your edition
All financial news and data tailored to specific country editions
